One of the key messages in terms of new therapies for childhood cancer is that clinical studies should be both demanded of industry and expected to…
In Conversation
We are calling strongly for a greater role in ensuring that the right treatments are approved, the ones that matter most to patients. The only way…
It is vital to ensure that we have the right culture and that our employees have a good understanding of the different parts of the business
A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the…
Jonny Ohlson, founder & CEO of Touchlight, discusses the genetic medicine revolution and the role of Touchlight in disrupting the field with its revolutionary DNA technology.
"It is incredibly important that we must, as the Napoleonic maxim goes, “manoeuvre according to circumstance.”"
“The UK and Europe are good markets, and we make sure we knock on the right doors with an appropriate value proposition. If we can create…
“As well as disease diagnosis, there is a lot that can be done around disease and therapy management using DNA data. For example, management of drug…
“We recently announced a partnership with Complement Pharmaceuticals to co-develop a complement inhibitor for neurodegenerative disorders, and our recent acquisition of Wilson Therapeutics fits perfectly within…
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the…
The UK is in itself a global life sciences hub and looked up to by the rest of the world. We have here the opportunity for…
I see technology as the enabler that creates new possibilities. Imaging devices are becoming more and more sophisticated and portable
